Shikiar Asset Management Inc. Sells 651 Shares of Danaher Co. (NYSE:DHR)

Shikiar Asset Management Inc. trimmed its position in shares of Danaher Co. (NYSE:DHR) by 8.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,721 shares of the conglomerate’s stock after selling 651 shares during the quarter. Shikiar Asset Management Inc.’s holdings in Danaher were worth $1,543,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Dakota Community Bank & Trust NA raised its position in Danaher by 16.4% during the 4th quarter. Dakota Community Bank & Trust NA now owns 320 shares of the conglomerate’s stock worth $73,000 after purchasing an additional 45 shares during the last quarter. Folger Nolan Fleming Douglas Capital Management Inc. increased its stake in shares of Danaher by 3.1% in the fourth quarter. Folger Nolan Fleming Douglas Capital Management Inc. now owns 4,037 shares of the conglomerate’s stock valued at $927,000 after buying an additional 120 shares during the period. Brooklyn Investment Group raised its position in shares of Danaher by 7.7% during the fourth quarter. Brooklyn Investment Group now owns 5,289 shares of the conglomerate’s stock worth $1,214,000 after acquiring an additional 378 shares during the last quarter. Sax Wealth Advisors LLC lifted its stake in shares of Danaher by 83.7% in the fourth quarter. Sax Wealth Advisors LLC now owns 3,260 shares of the conglomerate’s stock worth $748,000 after acquiring an additional 1,485 shares during the period. Finally, Merit Financial Group LLC boosted its holdings in Danaher by 14.3% in the fourth quarter. Merit Financial Group LLC now owns 10,050 shares of the conglomerate’s stock valued at $2,307,000 after acquiring an additional 1,260 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.

Danaher Stock Performance

NYSE DHR opened at $238.41 on Friday. The company has a fifty day moving average price of $234.99 and a 200-day moving average price of $253.37. The firm has a market cap of $172.20 billion, a price-to-earnings ratio of 45.50, a PEG ratio of 4.23 and a beta of 0.83. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. Danaher Co. has a 1 year low of $222.53 and a 1 year high of $281.70.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating the consensus estimate of $1.57 by $0.14. The firm had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The company’s revenue for the quarter was up 3.1% on a year-over-year basis. During the same quarter last year, the business posted $2.02 EPS. As a group, equities research analysts predict that Danaher Co. will post 7.49 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be paid a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. The ex-dividend date is Friday, December 27th. Danaher’s payout ratio is 20.61%.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on DHR shares. Bank of America raised shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 target price for the company in a research note on Friday, December 13th. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, December 14th. Stephens reiterated an “overweight” rating and issued a $315.00 target price on shares of Danaher in a report on Wednesday, October 23rd. Citigroup dropped their target price on shares of Danaher from $305.00 to $285.00 and set a “buy” rating on the stock in a research report on Monday, January 6th. Finally, Robert W. Baird reduced their price target on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $286.80.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.